Mankind Pharma (MANKIND.BO) Earnings Analysis
Mankind Pharma (MANKIND.BO) next reports earnings on 2026-07-30, consensus EPS 13.31 INR. Last quarter (2026-05-19) it beat with EPS 14 INR vs 10.15 INR est (+37.9%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E 55.00.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does MANKIND.BO next report earnings?
| Next earnings date | 2026-07-30 |
|---|---|
| Consensus EPS estimate | 13.31 INR |
| Revenue estimate | 39.70B |
MANKIND.BO earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-19 | 14 INR | 10.15 INR | +37.9% | Beat |
| 2025-09-29 | 12.38 INR | 12.71 INR | -2.6% | Miss |
| 2025-06-30 | 10.6 INR | 10.92 INR | -2.9% | Miss |
| 2025-05-21 | 10.18 INR | 9.87 INR | +3.1% | Beat |
| 2025-01-23 | 9.45 INR | 11.36 INR | -16.8% | Miss |
Beat rate: 2/5 (40%) over reported quarters with consensus data.
MANKIND.BO valuation and analyst view
| Trailing P/E | 55.00 |
|---|---|
| Trailing EPS | 46.378 INR |
| Price / book | 6.45 |
| Dividend yield | 0.04% |
| Market cap | 1054.33B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Mankind Pharma (MANKIND.BO)'s next earnings date?
Mankind Pharma is next scheduled to report on 2026-07-30, with a consensus EPS estimate of 13.31 INR and revenue estimate of 39.70B.
Did MANKIND.BO beat earnings last quarter?
In its 2026-05-19 report, MANKIND.BO posted EPS of 14 INR versus a 10.15 INR estimate — a beat of 37.9%.
What is MANKIND.BO's earnings track record?
Over the last 5 reported quarters with consensus data, MANKIND.BO beat estimates 2 times (40%).
What is MANKIND.BO's current P/E ratio and EPS?
MANKIND.BO trades at a trailing P/E of 55.00 on trailing EPS of 46.378220591907635 INR.
What do analysts rate MANKIND.BO?
MANKIND.BO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.